TY - JOUR
T1 - Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis
T2 - The Sustained Alcohol Use Post–Liver Transplant Score
AU - Lee, Brian P.
AU - Vittinghoff, Eric
AU - Hsu, Christine
AU - Han, Hyosun
AU - Therapondos, George
AU - Fix, Oren K.
AU - Victor, David W.
AU - Dronamraju, Deepti
AU - Im, Gene Y.
AU - Voigt, Michael D.
AU - Rice, John P.
AU - Lucey, Michael R.
AU - Eswaran, Sheila
AU - Chen, Po Hung
AU - Li, Zhiping
AU - Maddur, Haripriya
AU - Terrault, Norah A.
N1 - Funding Information:
Potential conflict of interest: Dr. Lucey received grants form AbbVie, Gilead Sciences, and Pharma Solutions. Dr. Victor consults for Vital Therapies. Dr. Therapondos consults for Medtronic. He advises and is on the Speakers Bureau for Novartis. He is on the Speakers Bureau for Eisai. He receives grants from Conatus Pharmaceuticals and Luminist. NT received institutional grant support from AbbVie, Gilead, Merck, Allergan and consults for Dova Pharmaceuticals.
Funding Information:
Received May 29, 2018; accepted September 23, 2018. Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.30478/suppinfo. Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases: University of California, San Francisco Liver Center P30 DK026743 and T32 DK060414 (Dr. Lee). © 2018 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.30478
Publisher Copyright:
© 2018 by the American Association for the Study of Liver Diseases.
PY - 2019/4
Y1 - 2019/4
N2 - Early liver transplant (LT) for alcohol-associated disease (i.e., without a specific sobriety period) is controversial but increasingly used. Using the multicenter American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) cohort, we aimed to develop a predictive tool to identify patients pretransplant with low risk for sustained alcohol use posttransplant to inform selection of candidates for early LT. We included consecutive ACCELERATE-AH LT recipients between 2012 and 2017. All had clinically diagnosed severe alcoholic hepatitis (AH), no prior diagnosis of liver disease or AH, and underwent LT without a specific sobriety period. Logistic and Cox regression, classification and regression trees (CARTs), and least absolute shrinkage and selection operator (LASSO) regression were used to identify variables associated with sustained alcohol use post-LT. Among 134 LT recipients for AH with median period of alcohol abstinence pre-LT of 54 days, 74% were abstinent, 16% had slips only, and 10% had sustained alcohol use after a median 1.6 (interquartile range [IQR]: 0.7-2.8) years follow-up post-LT. Four variables were associated with sustained use of alcohol post-LT, forming the Sustained Alcohol Use Post-LT (SALT) score (range: 0-11): >10 drinks per day at initial hospitalization (+4 points), multiple prior rehabilitation attempts (+4 points), prior alcohol-related legal issues (+2 points), and prior illicit substance abuse (+1 point). The C statistic was 0.76 (95% confidence interval [CI]: 0.68-0.83). A SALT score ≥5 had a 25% positive predictive value (95% CI: 10%-47%) and a SALT score of <5 had a 95% negative predictive value (95% CI: 89%-98%) for sustained alcohol use post-LT. In internal cross-validation, the average C statistic was 0.74. Conclusion: A prognostic score, the SALT score, using four objective pretransplant variables identifies candidates with AH for early LT who are at low risk for sustained alcohol use posttransplant. This tool may assist in the selection of patients with AH for early LT or in guiding risk-based interventions post-LT.
AB - Early liver transplant (LT) for alcohol-associated disease (i.e., without a specific sobriety period) is controversial but increasingly used. Using the multicenter American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) cohort, we aimed to develop a predictive tool to identify patients pretransplant with low risk for sustained alcohol use posttransplant to inform selection of candidates for early LT. We included consecutive ACCELERATE-AH LT recipients between 2012 and 2017. All had clinically diagnosed severe alcoholic hepatitis (AH), no prior diagnosis of liver disease or AH, and underwent LT without a specific sobriety period. Logistic and Cox regression, classification and regression trees (CARTs), and least absolute shrinkage and selection operator (LASSO) regression were used to identify variables associated with sustained alcohol use post-LT. Among 134 LT recipients for AH with median period of alcohol abstinence pre-LT of 54 days, 74% were abstinent, 16% had slips only, and 10% had sustained alcohol use after a median 1.6 (interquartile range [IQR]: 0.7-2.8) years follow-up post-LT. Four variables were associated with sustained use of alcohol post-LT, forming the Sustained Alcohol Use Post-LT (SALT) score (range: 0-11): >10 drinks per day at initial hospitalization (+4 points), multiple prior rehabilitation attempts (+4 points), prior alcohol-related legal issues (+2 points), and prior illicit substance abuse (+1 point). The C statistic was 0.76 (95% confidence interval [CI]: 0.68-0.83). A SALT score ≥5 had a 25% positive predictive value (95% CI: 10%-47%) and a SALT score of <5 had a 95% negative predictive value (95% CI: 89%-98%) for sustained alcohol use post-LT. In internal cross-validation, the average C statistic was 0.74. Conclusion: A prognostic score, the SALT score, using four objective pretransplant variables identifies candidates with AH for early LT who are at low risk for sustained alcohol use posttransplant. This tool may assist in the selection of patients with AH for early LT or in guiding risk-based interventions post-LT.
UR - http://www.scopus.com/inward/record.url?scp=85062491715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062491715&partnerID=8YFLogxK
U2 - 10.1002/hep.30478
DO - 10.1002/hep.30478
M3 - Article
C2 - 30561766
AN - SCOPUS:85062491715
VL - 69
SP - 1477
EP - 1487
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 4
ER -